Phathom (PHAT) | Financial Analysis & Statements
Phathom Pharmaceuticals Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
57.6M
Gross Profit
49.9M
86.72%
Operating Income
-5.9M
-10.29%
Net Income
-21.1M
-36.73%
EPS (Diluted)
$-0.29
Balance Sheet Metrics
Total Assets
259.1M
Total Liabilities
697.3M
Shareholders Equity
-438.2M
Cash Flow Metrics
Operating Cash Flow
-1.2M
Free Cash Flow
-5.1M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Phathom Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 175.1M | 55.3M | 682.0K | 0 | 0 |
| Cost of Goods Sold | 22.6M | 8.0M | 167.0K | 0 | - |
| Gross Profit | 152.5M | 47.3M | 515.0K | 0 | - |
| Gross Margin % | 87.1% | 85.6% | 75.5% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 32.8M | 34.1M | 49.9M | 71.4M | 72.3M |
| Selling, General & Administrative | 279.7M | 290.7M | 117.9M | 101.0M | 62.7M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 312.5M | 324.7M | 167.8M | 172.4M | 135.1M |
| Operating Income | -160.0M | -277.5M | -167.3M | -172.4M | -135.1M |
| Operating Margin % | -91.4% | -502.2% | -24,532.6% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 7.0M | 15.2M | 7.9M | 2.1M | 41.0K |
| Interest Expense | 68.1M | 72.0M | 42.0M | 27.3M | 6.8M |
| Other Non-Operating Income | -190.0K | -8.0K | -188.0K | -110.0K | -2.1M |
| Pre-tax Income | -221.2M | -334.3M | -201.6M | -197.7M | -143.9M |
| Income Tax | - | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -221.2M | -334.3M | -201.6M | -197.7M | -143.9M |
| Net Margin % | -126.3% | -605.1% | -29,558.9% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | -152.5M | -261.5M | -159.0M | -169.8M | -136.6M |
| EPS (Basic) | - | $-5.29 | $-3.93 | $-5.05 | $-3.89 |
| EPS (Diluted) | - | $-5.29 | $-3.93 | $-5.05 | $-3.89 |
| Basic Shares Outstanding | - | 63176210 | 51289092 | 39118215 | 37002959 |
| Diluted Shares Outstanding | - | 63176210 | 51289092 | 39118215 | 37002959 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Phathom Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 130.0M | 297.3M | 381.4M | 155.4M | 183.3M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 78.1M | 38.8M | 1.6M | 0 | - |
| Inventory | 5.5M | 3.2M | 1.2M | 0 | - |
| Other Current Assets | 15.4M | 20.9M | 13.2M | 5.1M | 3.3M |
| Total Current Assets | 229.0M | 360.1M | 397.4M | 160.5M | 186.5M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 1.5M | 1.5M | 1.5M | 2.3M | 1.9M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 26.5M | 16.1M | 12.8M | 804.0K | 341.0K |
| Total Non-Current Assets | 30.2M | 18.2M | 16.4M | 4.3M | 2.9M |
| Total Assets | 259.1M | 378.3M | 413.8M | 164.8M | 189.4M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 5.0M | 10.5M | 12.6M | 10.0M | 5.2M |
| Short-term Debt | 648.0K | 501.0K | 726.0K | 708.0K | 487.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 34.7M | 19.8M | 7.1M | - | - |
| Total Current Liabilities | 132.0M | 85.7M | 38.8M | 26.2M | 18.9M |
| Non-Current Liabilities | |||||
| Long-term Debt | 211.2M | 201.4M | 138.3M | 96.4M | 90.9M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 354.1M | 344.8M | 309.5M | 117.0M | 7.5M |
| Total Non-Current Liabilities | 565.3M | 546.2M | 447.8M | 213.4M | 98.4M |
| Total Liabilities | 697.3M | 631.9M | 486.6M | 239.6M | 117.3M |
| Equity | |||||
| Common Stock | 6.0K | 6.0K | 5.0K | 3.0K | 3.0K |
| Retained Earnings | -1.5B | -1.3B | -928.7M | -727.1M | -529.4M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | -438.2M | -253.6M | -72.8M | -74.8M | 72.2M |
| Key Metrics | |||||
| Total Debt | 211.8M | 201.9M | 139.0M | 97.1M | 91.3M |
| Working Capital | 96.9M | 274.4M | 358.7M | 134.3M | 167.6M |
Balance Sheet Composition
Phathom Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -221.2M | -334.3M | -201.6M | -197.7M | -143.9M |
| Depreciation & Amortization | 633.0K | 795.0K | 575.0K | 620.0K | 521.0K |
| Stock-Based Compensation | 28.7M | 24.0M | 45.0M | 24.1M | 16.8M |
| Working Capital Changes | -18.0M | -8.2M | -5.9M | 8.3M | -9.5M |
| Operating Cash Flow | -172.7M | -260.5M | -129.8M | -143.6M | -130.6M |
| Investing Activities | |||||
| Capital Expenditures | -229.0K | -135.0K | -1.6M | -1.0M | -328.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -229.0K | -135.0K | -1.6M | -1.0M | -328.0K |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 0 | 59.4M | 39.3M | 0 | 96.9M |
| Debt Repayment | - | - | - | 0 | -54.1M |
| Financing Cash Flow | -1.9M | 181.2M | 367.5M | 120.0M | 42.8M |
| Free Cash Flow | -167.0M | -266.9M | -139.2M | -147.6M | -148.8M |
| Net Change in Cash | -174.8M | -79.5M | 236.0M | -24.6M | -88.2M |
Cash Flow Trend
Phathom Key Financial Ratios
Valuation Ratios
Forward P/E
8.34
Price to Book
-2.05
Price to Sales
5.84
PEG Ratio
8.34
Profitability Ratios
Profit Margin
-126.35%
Operating Margin
-10.30%
Return on Equity
50.49%
Return on Assets
-31.37%
Financial Health
Current Ratio
1.73
Debt to Equity
-1.34
Beta
0.61
Per Share Data
EPS (TTM)
$-3.03
Book Value per Share
$-6.14
Revenue per Share
$2.40
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| PHAT | 965.9M | - | -2.05 | 50.49% | -126.35% | -1.34 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Recursion | 1.9B | -2.44 | 1.64 | -59.54% | 4.45% | 6.89 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
Financial data is updated regularly. All figures are in the company's reporting currency.






